Preliminary data on its pan-cancer blood test appear surprisingly competitive.
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.